Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Bupropion HCI, EON Labs Inc · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Bupropion HCI ER Tablets, 150 mg |
| 2 | ACTIVE_COMPARATOR | WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg |
| Name | Type | Description |
|---|---|---|
| Bupropion HCI ER Tablets, 150 mg; EON Labs Inc. | DRUG | - |
| WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline | DRUG | - |
Inclusion Criteria: * No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: * Positive test results for HIV or hepatitis B or C. * Treatment for drug or alcohol dependence.
Bupropion HCI, EON Labs Inc is an extended-release tablet formulation of bupropion hydrochloride, 150 mg, developed by Novartis AG (ticker NVS). It is a small molecule in the psychiatry therapeutic area, studied for depression. The product is also known as Bupropion HCI ER Tablets, 150 mg; EON Labs Inc.
Bupropion HCI, EON Labs Inc is used for depression. It is an extended-release tablet formulation of bupropion hydrochloride, 150 mg, developed by Novartis AG (NVS). The clinical program in this dataset includes a relative bioavailability study in healthy adult volunteers under fasting conditions.
Bupropion HCI, EON Labs Inc targets SLC6A3 and SLC6A2. It is an inhibitor of these transporters. SLC6A3 is the dopamine transporter and SLC6A2 is the norepinephrine transporter. This mechanism is consistent with its development for depression by Novartis AG (NVS).
Bupropion HCI, EON Labs Inc is developed by Novartis AG, which trades under the ticker NVS. The product is an extended-release tablet formulation of bupropion hydrochloride, 150 mg, and is listed in the psychiatry therapeutic area for depression.
Bupropion HCI, EON Labs Inc is in Phase 1 development. The program includes one completed Phase 1 trial. It is investigational and is not described as approved. The trial was a relative bioavailability study of the 150 mg sustained-release tablets under fasting conditions.
Bupropion HCI, EON Labs Inc has been studied in one completed Phase 1 trial, NCT00864981, titled A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting Conditions. It enrolled 32 healthy adult volunteers, was randomized, and used an active-controlled design.